Albunorm 25% is used to help manage conditions where the body has a severely reduced concentration of plasma protein, known as hypoalbuminemia. The medication may be employed to support the maintenance of blood volume in critical scenarios, such as following extensive burns or major surgery, or in the management of shock.

Its therapeutic role is to support the necessary fluid balance and circulatory volume when the patient is unable to maintain adequate plasma protein levels. The drug is supported for use in: hypovolemia, hypoalbuminemia from various causes, and adjunctive treatment for conditions like acute nephrosis and fluid imbalance in Adult Respiratory Distress Syndrome (ARDS).

Quick Fact: Relief for Volume Deficiency Albunorm 25% is used to help manage the rapid loss of blood volume in acute situations. It may help restore fluid balance and support blood pressure maintenance when circulating protein levels are low.

Eligibility to use Albunorm 25% (Human Albumin 25%) is determined by official regulations, primarily focusing on patient allergies and the risk of circulatory compromise.

Contraindicated Populations (Cannot Use)

Classification	Population/Condition
Absolute Prohibition	Patients with known hypersensitivity to Human Albumin preparations or to any excipient in the formulation.

Populations Requiring Conditional Use

Conditions that pose a special risk due to the drug's effect of expanding blood volume require close monitoring or restricted use:

• Cardiovascular Conditions: Use is cautioned against in patients with severe cardiac failure or severe anemia, as they face an increased risk of circulatory overload (hypervolemia).
• Organ Impairment: Patients with severe renal or hepatic impairment require careful monitoring for fluid and electrolyte imbalance.

Age-Related Eligibility

Age Group	Eligibility Status
Adults	Established for use.
Pediatric Patients	Permitted, but dose must be strictly calculated based on weight.
Pregnancy/Lactation	Permitted if clearly needed; caution advised during breastfeeding.

Interactions with other medicines and products

Official regulatory information for Albunorm 25% (Human Albumin) primarily focuses on physical and chemical incompatibilities and procedural restrictions related to mixing and administration. No specific pharmacological interactions with other medicinal products are known or documented in authoritative government regulatory sources.

Mixing and Incompatibility Constraints

The following co-administration restrictions are explicitly stated in product labeling and related government monographs:

Substance or Product Category	Interaction Restriction	Constraint Basis
Sterile Water for Injection	Must not be used for dilution	High risk of hemolysis and acute renal failure
Protein Hydrolysates / Amino Acid Solutions	Should not be mixed	Incompatibility risk
Solutions Containing Alcohol	Should not be mixed	Incompatibility risk
Whole Blood or Packed Red Cells	Should not be mixed	Procedural constraint; administer separately

Permitted Diluents

Albunorm 25% may be diluted only with isotonic solutions, such as normal saline (0.9% sodium chloride) or 5% dextrose (glucose). These established procedural constraints define the regulatory structure for safe use, ensuring that the integrity of the solution is maintained during preparation and administration.

How Albunorm 25% Works

Albunorm 25% is a hyper-oncotic solution of human serum albumin, functioning primarily through three distinct mechanistic domains. The administered albumin significantly increases the total concentration of non-diffusible proteins within the intravascular compartment, thereby elevating the colloid osmotic pressure (COP) of the blood. This physical effect establishes an osmotic gradient, contributing to fluid redistribution from the interstitial spaces (e.g., fluid-rich compartments) into the bloodstream, impacting intravascular volume.

Secondly, the albumin protein acts as a non-specific carrier molecule due to its multiple high-affinity binding sites. This action enhances the systemic transport and mobilization of a diverse range of endogenous and exogenous ligands, including fatty acids, hormones, bilirubin, and certain toxins. This modifies the distribution kinetics of various circulating compounds.

Finally, the albumin molecule possesses an intrinsic structure, specifically the Cysteine-34 ( Cys^34) sulfhydryl group, which engages the protein's capacity as a major plasma free radical scavenger and redox buffer. This non-enzymatic property impacts the reactivity of circulating reactive oxygen and nitrogen species within the plasma.

Albunorm 25% is a human albumin solution administered exclusively by the intravenous route (infusion into a vein). A qualified healthcare professional must manage the treatment, as the dosage, concentration, and infusion rate must be carefully tailored to the patient’s individual needs, body size, and the severity of the condition being treated.

Preparation and Administration

• Visual Inspection: Before administration, the solution must be visually inspected. It should appear clear, slightly viscous, and range from yellow to amber or green. Do not use the solution if it is cloudy or contains particulate matter, as this may indicate instability or contamination.
• Temperature: If large volumes are to be administered, the product should be warmed to room or body temperature before infusion.
• Dilution: Albunorm 25% may be administered directly. If dilution is necessary, a sterile isotonic solution such as 0.9% sodium chloride or 5% glucose (dextrose) should be used. Crucially, the solution must not be diluted with sterile water for injection as this carries a risk of causing hemolysis (destruction of red blood cells) in the recipient.
• Infusion Rate: The infusion rate is adjusted by the physician based on the clinical indication and the patient's hemodynamic status. In the absence of shock, a typical initial rate of 1 to 2 mL per minute is often indicated for 25% albumin solutions. When treating shock, a more rapid infusion may be necessary.

Monitoring

Due to its hyperoncotic nature, Albunorm 25% exerts a powerful effect on plasma volume, which may be up to four times the volume of the albumin solution administered. The patient's response and hemodynamic status must be regularly monitored, including arterial blood pressure, pulse rate, central venous pressure, and urine output, to prevent hypervolemia (circulatory overload). At the first signs of cardiovascular overload (e.g., headache, difficulty breathing), the infusion must be stopped immediately.

Research Evidence for Acute Volume Deficiency (Hypovolemia)

This section will summarize the structure of clinical research, including large-scale Randomized Controlled Trials (RCTs) and systematic reviews, that have evaluated the use of Albunorm 25% for volume replacement in clinical studies involving critically ill patients.

Researchers were involved in studies that examined patient populations, including critically ill adults and children, who were experiencing volume deficiency often related to conditions such as sepsis, trauma, or major surgery. Studies primarily monitored all-cause mortality and measurements related to blood circulation.

Findings describe patterns observed in the studies, where short-term measurements of blood pressure and cardiac function were reported for patients receiving albumin or comparator fluids. In the large trials and subsequent research, findings regarding the outcomes of all-cause mortality, when compared to non-protein fluids, were mixed. The scientific discussion remains active regarding the overall patterns observed in mortality outcomes when comparing albumin to other fluid types used in the research.

Studies Examining Low Plasma Protein Levels (Hypoalbuminemia)

This area of the section will outline the evidence derived from clinical trials and reviews that focus on the administration of Human Albumin 25% to address severely reduced plasma protein concentration across various complex clinical scenarios. Outcomes related to systemic or functional imbalance were monitored, including the achievement of normal plasma protein levels and the resolution of severe fluid retention (edema).

Research highlights changes measured during the study period; administration was observed in some studies to lead to short-term reported increases in measured plasma albumin levels. However, reported observations regarding long-term mortality or overall clinical course showed inconsistent patterns across different disease states when linked to albumin correction.

Evidence for Specialized and Adjunctive Uses

This section will detail the specific research conducted on the use of Albunorm 25% in certain high-risk situations, such as preventing volume shifts following large-volume fluid removal (paracentesis) in patients with cirrhosis, and its use in conjunction with diuretics for fluid management in conditions like Acute Nephrosis.

Research in Cirrhosis Patients Post-Paracentesis

Randomized controlled trials were studied for use in patients with chronic liver disease (cirrhosis) undergoing the removal of large volumes of abdominal fluid. The primary outcome monitored was the prevention of post-procedural circulatory dysfunction. Multiple studies monitored changes during the study period and findings describe patterns observed suggesting an association between albumin administration and lower measurements of circulatory dysfunction compared to alternatives following the procedure.

Scientific Uncertainty and Areas for Future Research

Across the spectrum of research, findings were mixed, particularly regarding outcomes related to systemic or functional imbalance in critical care settings. Comparative evidence is lacking for certain administration scenarios, and evidence quality varies across studies, leading to low certainty for several long-term outcomes. Research is ongoing to better define the specific clinical circumstances and patient characteristics where the administration of albumin has been studied or where evidence is still required.

Common questions about Albunorm 25% (FAQ)

---

Q: Is Albunorm 25% the same as other albumin products?

Albunorm 25% is the specific brand name for a sterile solution of Human Albumin 25%. The active ingredient, Human Albumin, is a protein derived from human plasma. This core component is standardized and is the same substance found in other commercially available human albumin products of the same concentration, though brand names and stabilizing agents may vary.

---

Q: How is Albunorm 25% different from a blood transfusion?

Albunorm 25% is a single-component product that contains only highly purified Human Albumin protein in a sterile solution. A blood transfusion involves more complex products, such as whole blood or packed red cells, which contain components like red blood cells. Official regulatory constraints explicitly state that Human Albumin should not be mixed with whole blood or packed red cells during administration.

---

Q: How long does the effect of Albunorm 25% typically last?

Official information on how the body processes the drug (pharmacokinetics) indicates that the human albumin component has an approximate half-life of 15 to 20 days. The half-life refers to the time it takes for half the amount of the protein to be naturally eliminated or broken down by the body.

---

Q: Are there any long-term effects associated with Albunorm 25% use?

Official regulatory safety summaries primarily focus on immediate and short-term reactions associated with the infusion. They do not document specific long-term effects of Albunorm 25% in the regulatory texts. The product is derived from human plasma, and appropriate sourcing and manufacturing precautions are taken to reduce the risk of infectious agents.

---

Q: Can Albunorm 25% be given at home?

The product requires administration by a qualified healthcare professional due to the need for close monitoring to check for signs of volume overload, such as changes in blood pressure. The first dose is typically given in a controlled clinical setting, and any subsequent administration outside of that setting would require specific medical supervision.

---

Q: Is Albunorm 25% given as a single treatment or usually multiple doses?

Regulatory usage conditions indicate that the dose, concentration, and infusion rate must be carefully and uniquely tailored to the individual patient’s body size, specific needs, and illness severity. The initial dose may be followed by additional doses if the first response is insufficient, as the total treatment plan is determined by the patient's individual response and condition.

---

Q: Can people with kidney conditions use Albunorm 25%?

The administration of Human Albumin has been examined in research for use in certain kidney conditions, such as Acute Nephrosis. Official safety precautions note that patients with severe renal impairment require close monitoring for potential fluid and electrolyte imbalances because of the drug's effect of expanding circulating blood volume.

---

Q: Is the use of Albunorm 25% supported by major health organizations?

Yes. The active ingredient, Human Albumin, is recognized globally for its foundational role in critical care. The World Health Organization (WHO) classifies Human Albumin on its Model List of Essential Medicines.

---

Q: Does Albunorm 25% have any effect on blood clotting?

Regulatory documents indicate that when large volumes of albumin are replaced, monitoring of coagulation factors and haematocrit (the proportion of red blood cells in the blood) is necessary to ensure stability. This monitoring is part of the established protocol for safe administration.

---

Q: If I am a vegetarian or vegan, can I receive Albunorm 25%?

The active ingredient, Human Albumin, is exclusively derived from large pools of donated human plasma. The product is classified as a human blood product derivative and contains biological material of human origin.

---

Q: What kind of studies have been done on Albunorm 25%?

Clinical research has been conducted across three primary areas. These include studies on the use of albumin in volume replacement for critically ill patients; trials addressing severely low plasma protein levels, or hypoalbuminemia; and research into specific adjunctive uses, such as preventing complications after large-volume fluid removal in patients with cirrhosis.

---

Q: What is the process of getting an Albunorm 25% infusion like?

The product is administered as a sterile solution directly into a vein. During the process, a healthcare professional carefully monitors the patient’s response, including checking arterial blood pressure, pulse rate, and other signs of circulatory function. This is necessary to help prevent the possibility of fluid overload.

---

Q: How quickly does Albunorm 25% start working in the body?

The main action is a rapid fluid movement from body tissues into the blood vessels, leading to an increase in circulating blood volume. In cases of acute volume loss, the effect is expected to be immediate, with regulatory information advising that a measurable response should be achieved within 15 to 30 minutes after the initial dose.

---

Q: Is there a limit to how many times a person can receive Albunorm 25%?

There is no fixed limit on the total number of administrations, but the official guidelines set limits on the amount that may be administered in a continuous period. The concentration, dosage, and frequency are strictly adjusted by a physician based on the patient's individual condition.

---

Q: What are the main findings from research on Albunorm 25% in critically ill patients?

Research indicates that while short-term measurements of blood pressure and circulatory function were reported for patients receiving albumin, studies examining outcomes such as overall mortality, when compared to other non-protein fluids, have shown mixed findings across various research in critically ill patients.

---

Q: Can Albunorm 25% affect laboratory test results?

Yes, because this product directly increases the amount of albumin in the bloodstream, it can cause an artificial increase in the results of blood tests that measure plasma albumin levels.

How to Store and Dispose of Albunorm 25%

Albunorm 25% (Human Albumin) requires precise storage and handling to maintain its stability as defined in regulatory labeling.

---

Storage Requirements

Condition	Regulatory Requirement
Temperature Range	Store between 2 C to 25 C (36 F to 77 F). Do not store above 25 C.
Environmental Protection	Store in the original container to protect from light and do not freeze.
Child Safety	Keep out of the sight and reach of children.

Handling and Disposal

The medicine is for single use only. The solution must be visually inspected and must not be used if it appears cloudy, discolored, or contains deposits. Once the container is opened, the contents must be used immediately; the infusion must be completed within 4 hours. Any unused portion must be discarded according to local regulations for pharmaceutical waste.